Development of highly potent human monoclonals for RSV immunoprophylaxis
Ended Project Grant Awarded Last action
- Award ID
- R43AI136272
- Recipient
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $424,353
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $482,902.00 Federal
- -$58,549.00 Non-federal
- Place of performance
- San Diego, CA 92121, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$58,549 | $0 | |
| Amendment | -$58,549 | -$58,549 | |
| Amendment | $300,000 | $0 | |
| Original award | $300,000 | $0 |
Quick answers
Who received award R43AI136272?
R43AI136272 was awarded to Mapp Biopharmaceutical, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 15, 2018.
How much is award R43AI136272 worth?
$424,353 has been obligated on R43AI136272: $482,902 in federal funding and -$58,549 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award